



NEONATAL




URSODEOXYCHOLIC ACID

This document should be read in conjunction with this [DISCLAIMER](#)

Unrestricted: Any prescriber may initiate treatment as per guideline

Presentation	Oral Suspension: 50mg/mL
Classification	Hydrophilic bile acid which alters bile acid composition, increases bile acid output and bile flow and decreases reuptake of bile products from the gut. May protect liver cells from damaging activity of toxic bile acids in chronic liver disease.
Indication	Treatment of cholestasis associated with parenteral nutrition, biliary atresia, and cystic fibrosis.
Contraindication	Contraindicated in patients with complete biliary obstruction
Dose	Oral: 10 to 15 mg/kg/dose every 12 hours
Monitoring	Monitor liver function tests and serum bilirubin. Observe stool colour.
Administration	Oral or via intragastric tube. May be given at any time in regard to feeds.
Adverse Reactions	Common: Nausea, vomiting, constipation, flatulence, Infrequent: Transient increase in liver function test values. Rare: Transient hypercholesterolaemia.
Storage	Closed bottle: Store below 25°C. Discard suspension 4 months after opening (write date opened on bottle).
Interactions	Antacids which contain aluminium bind to ursodeoxycholic acid and reduce its absorption.
Notes	Consider fat-soluble vitamin supplementation if required to prevent fat-soluble vitamin deficiency during cholestasis.

References	<p>Australian Medicines Handbook. Ursodeoxycholic acid. In: Australian Medicines Handbook [Internet]. Adelaide (South Australia): Australian Medicines Handbook; 2019 [cited 2019 Jul 03]. Available from: https://amhonline.amh.net.au/</p> <p>Truven Health Analytics. Phenytoin. In: NeoFax [Internet]. Greenwood Village (CO): Truven Health Analytics; 2019 [cited 2019 Jul 04]. Available from: https://neofax.micromedexsolutions.com/</p>
-------------------	---

Document owner:	Head of Department - Neonatology		
Author / Reviewer:	KEMH & PCH Pharmacy / Neonatology Directorate		
Date first issued:	Jan 2001	Version:	3.0
Last reviewed:	July 2019	Next review date:	July 2022
Endorsed by:	Neonatal Directorate Management Group	Date:	July 2019
Standards Applicable:	NSQHS Standards: 1  Governance 3  Infection Control 4  Medication Safety;		
Printed or personally saved electronic copies of this document are considered uncontrolled. Access the current version from the WNHS website.			

© Department of Health Western Australia 2019